Firefly Fund Co-Founders Pam & Chris Andrews enjoyed their recent Firefly Chat with Thomas Kirkegaard Jensen Ph.D., Co-Founder and Chief Scientific Officer of Orphazyme and Kim Stratton, CEO of Orphazyme. We know you will like getting to know Thomas and Kim as much as we did and that you will also appreciate hearing about the history of Orphazyme and the development of Arimoclomol, a novel treatment for Niemann Pick Type C disease that has completed a Phase three clinical trial and recently filed a New Drug Application (NDA) with the USFDA. Orphazyme is a biopharmaceutical company that translates scientific discoveries into late-stage clinical development programs impacting lives of patients with orphan diseases and their families.